Credit Suisse
downgraded Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) from a Neutral rating to
an Underperform rating and cut its price target from $8 to $6. The stock price lost 57 cents to $6.45.
Ariad Pharmaceuticals downgraded
December 11, 2014 at 13:32 PM EST